Results 291 to 300 of about 54,594 (319)
Some of the next articles are maybe not open access.
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
The Lancet Oncology, 2022 L. Budde, L. Sehn, M. Matasar, S. Schuster, S. Assouline, P. Giri, J. Kuruvilla, M. Canales, S. Dietrich, K. Fay, M. Ku, L. Nastoupil, C. Cheah, M. Wei, S. Yin, Chi-Chung Li, Huang Huang, A. Kwan, E. Penuel, N. Bartlett +19 moresemanticscholar +1 more sourceBispecific dendritic-T cell engager potentiates anti-tumor immunity
CellYuval Shapir Itai, Oren Barboy, Ran Salomon, A. Bercovich, Ken Xie, E. Winter, T. Shami, Z. Porat, Neta Erez, A. Tanay, I. Amit, R. Dahan +11 moresemanticscholar +1 more sourceFunctional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors
Nature Cancer, 2022 B. Herpers, Berina Eppink, M. James, C. Cortina, Adrià Cañellas-Socias, S. Boj, Xavier Hernando-Momblona, D. Głodzik, R. Roovers, M. van de Wetering, Carina Bartelink-Clements, Vanessa Zondag-van der Zande, Jara García Mateos, K. Yan, L. Salinaro, Abdul Basmeleh, S. Fátrai, D. Maussang, J. J. Lammerts van Bueren, I. Chicote, G. Serna, L. Cabellos, L. Ramírez, P. Nuciforo, R. Salazar, Cristina Santos, A. Villanueva, Camille Stephan-Otto Attolini, E. Sancho, H. G. Pálmer, J. Tabernero, M. Stratton, J. de Kruif, T. Logtenberg, H. Clevers, L. Price, R. Vries, E. Batlle, M. Throsby +38 moresemanticscholar +1 more sourceIL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.
Neuro-OncologyA. J. Hou, Ryan M Shih, Benjamin R. Uy, Amanda Shafer, Ze Nan L Chang, Begonya Comin-Anduix, Miriam Guemes, Zoran Galic, S. Phyu, Hideo Okada, K. Grausam, Joshua J. Breunig, Christine E. Brown, David A. Nathanson, R. Prins, Y. Chen +15 moresemanticscholar +1 more source
